Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.37 |
| ▸ | SLC9A5 | Q14940 | 1/20 | 0.36 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21225333 | 1.00 | TSHR (0.41) | TSHRSLC9A1MAP3K14SLC9A5SLC9A2 | |
| SCHEMBL29421547 | 0.85 | DPP4 (0.44) | MAOBMEN1NPC1POLBRAB9A | |
| SCHEMBL21225332 | 0.85 | DPP4 (0.44) | MAOBMEN1NPC1POLBRAB9A | |
| SCHEMBL21224530 | 0.81 | TSHR (0.42) | TSHRSLC9A1MAP3K14SLC9A5SLC9A2 | |
| SCHEMBL29520511 | 0.81 | TSHR (0.42) | TSHRSLC9A1MAP3K14SLC9A5SLC9A2 | |
| SCHEMBL22103251 | 0.80 | KDM4E (0.42) | TSHRMAOBPOLBMTNR1AMTNR1B | |
| SCHEMBL30843187 | 0.80 | MAOB (0.38) | PIK3CAPIK3CBMAOBMEN1NPC1 | |
| SCHEMBL6956175 | 0.75 | MTNR1B (0.37) | TSHRSLC9A1MAP3K14SLC9A5SLC9A2 | |
| SCHEMBL3006411 | 0.73 | HTR2C (0.35) | PRKCIRAB9A | |
| SCHEMBL29413897 | 0.73 | HTR2C (0.35) | PRKCIRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2025-09-11 | — | — | US | disclosed |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| WO-2025043191-A1 | PRC2 INHIBITORS FOR USE IN TREATING SICKLE CELL DISEASE | ORIC PHARMACEUTICALS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| EP-4043466-B1 | PRC2 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-08-21 | — | — | EP | disclosed |
| EP-4404932-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | Oric Pharmaceuticals, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| CN-112004816-B | PRC2 inhibitors | 米拉蒂医疗股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230137025-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| WO-2023049724-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | ORIC PHARMACEUTICALS, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| WO-2023049723-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | ORIC PHARMACEUTICALS, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| US-11485738-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-11-01 | — | — | US | disclosed |
| EP-4043466-A1 | PRC2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| EP-3746446-B1 | PRC2 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2022-05-11 | — | — | EP | disclosed |
| CN-114269748-A | Imidazo [1,2-c ] pyrimidine derivatives as PRC2 inhibitors for the treatment of cancer | 米拉蒂医疗股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | TSHR 4145/4885SLC9A1 3517/4885MAP3K14 1189/4885 |
| US-11485738-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | TSHR 4715/4885SLC9A1 3354/4885MAP3K14 2391/4885 |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | TSHR 4715/4885SLC9A1 3354/4885MAP3K14 2391/4885 |
| US-20230137025-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | TSHR 4715/4885SLC9A1 3354/4885MAP3K14 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.